The invention relates to self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpfl systems. The invention also relates to genetically modified cells related to the same. The invention also relates to methods of controlling Cas9 expression in a cell related to the same. The invention also relates to methods of genetically modifying a cell related to the same. The invention also relates to nucleic acids for use in a self-inactivating CRISPR/Cas or CRISPR/Cpfl system. The invention also relates to pharmaceutical compositions related to the same.L'invention concerne des systèmes CRISPR/Cas et des compositions ciblant le gène de la dystrophine. L'invention concerne également des procédés d'utilisation des systèmes CRISPR/Cas, des vecteurs et des compositions utilisés dans des procédés d'ingénierie génomique pour corriger un gène mutant de la dystrophine, et pour traiter la dystrophie musculaire de Duchenne.
